Nothing Special   »   [go: up one dir, main page]

EA201992090A1 - ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА - Google Patents

ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА

Info

Publication number
EA201992090A1
EA201992090A1 EA201992090A EA201992090A EA201992090A1 EA 201992090 A1 EA201992090 A1 EA 201992090A1 EA 201992090 A EA201992090 A EA 201992090A EA 201992090 A EA201992090 A EA 201992090A EA 201992090 A1 EA201992090 A1 EA 201992090A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
quinolin
cancer treatment
salts
imidazo
Prior art date
Application number
EA201992090A
Other languages
English (en)
Other versions
EA038233B1 (ru
Inventor
Курт Гордон Пайк
Бернар Кристоф Барлаам
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201992090A1 publication Critical patent/EA201992090A1/ru
Publication of EA038233B1 publication Critical patent/EA038233B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение в общем относится к соединениям формулы (I)и их фармацевтически приемлемым солям, где Rимеет значение, определенное в данном документе. Изобретение также относится к применению соединений формулы (I) и их солей для лечения или предотвращения заболеваний, опосредованных ATM, включая рак. Описание дополнительно относится к фармацевтическим композициям, содержащим замещенные соединения имидазо[4,5-c]хинолин-2-она и их фармацевтически приемлемые соли; и к наборам, содержащим такие соединения и соли.
EA201992090A 2017-03-16 2018-03-15 ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА EA038233B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472080P 2017-03-16 2017-03-16
PCT/EP2018/056516 WO2018167203A1 (en) 2017-03-16 2018-03-15 Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
EA201992090A1 true EA201992090A1 (ru) 2020-03-06
EA038233B1 EA038233B1 (ru) 2021-07-28

Family

ID=61801891

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992090A EA038233B1 (ru) 2017-03-16 2018-03-15 ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА

Country Status (25)

Country Link
US (2) US20200087300A1 (ru)
EP (1) EP3596076A1 (ru)
JP (1) JP2020514344A (ru)
KR (1) KR20190129923A (ru)
CN (1) CN110431139B (ru)
AU (1) AU2018234985B2 (ru)
BR (1) BR112019018723A2 (ru)
CA (1) CA3055258A1 (ru)
CL (1) CL2019002527A1 (ru)
CO (1) CO2019010029A2 (ru)
CR (1) CR20190429A (ru)
DO (1) DOP2019000228A (ru)
EA (1) EA038233B1 (ru)
EC (1) ECSP19066134A (ru)
IL (1) IL269272A (ru)
JO (1) JOP20190209A1 (ru)
MA (1) MA49884A (ru)
MX (1) MX2019010898A (ru)
NI (1) NI201900094A (ru)
PE (1) PE20191486A1 (ru)
PH (1) PH12019502086A1 (ru)
SG (1) SG11201908065YA (ru)
TW (1) TW201843151A (ru)
UA (1) UA124554C2 (ru)
WO (1) WO2018167203A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV15575A (lv) 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor
KR20230026478A (ko) * 2020-09-21 2023-02-24 웨이 중 혈액-뇌 장벽 투과능을 가진 치환된 1-(3,3-디플루오로피페리딘-4-일)-이미다조[4,5-c] 퀴놀린-2-온 화합물
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
NZ330868A (en) 1996-02-13 2000-01-28 Zeneca Ltd 4-phenoxy, phenylthio or phenylamino substituted quinazoline derivatives ane medicaments useful as VEGF inhibitors
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
CA2763821A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1h-imidazo[4,5-c]quinolinone derivatives
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (ru) * 2014-05-08 2018-04-21
NZ736641A (en) * 2015-04-02 2024-09-27 Merck Patent Gmbh Imidazolonyl quinolines and use thereof as atm kinase inhibitors
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Also Published As

Publication number Publication date
US20200087300A1 (en) 2020-03-19
BR112019018723A2 (pt) 2020-04-07
CO2019010029A2 (es) 2019-09-30
SG11201908065YA (en) 2019-09-27
TW201843151A (zh) 2018-12-16
CN110431139B (zh) 2022-07-05
IL269272A (en) 2019-11-28
ECSP19066134A (es) 2019-09-30
MX2019010898A (es) 2019-11-07
EA038233B1 (ru) 2021-07-28
EP3596076A1 (en) 2020-01-22
MA49884A (fr) 2020-06-24
AU2018234985B2 (en) 2020-04-02
CL2019002527A1 (es) 2019-11-22
DOP2019000228A (es) 2019-09-30
AU2018234985A1 (en) 2019-10-24
UA124554C2 (uk) 2021-10-05
JP2020514344A (ja) 2020-05-21
WO2018167203A1 (en) 2018-09-20
JOP20190209A1 (ar) 2019-09-12
PH12019502086A1 (en) 2020-03-09
KR20190129923A (ko) 2019-11-20
CN110431139A (zh) 2019-11-08
NI201900094A (es) 2020-03-18
US20210347775A1 (en) 2021-11-11
CA3055258A1 (en) 2018-09-20
PE20191486A1 (es) 2019-10-18
CR20190429A (es) 2019-11-12

Similar Documents

Publication Publication Date Title
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
MX2018003215A (es) Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
EA201790088A1 (ru) Ингибиторы syk
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
ATE517882T1 (de) Chinolinderivate
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
EA201992577A1 (ru) 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
EA202090644A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3K
EA202092600A1 (ru) Тетрациклические гетероарильные соединения